Narcisa Mandras Selected Research

Infections

2/2024	Is Silver Addition to Scaffolds Based on Polycaprolactone Blended with Calcium Phosphates Able to Inhibit Candida albicans and Candida auris Adhesion and Biofilm Formation?
8/2023	Tuning of Silver Content on the Antibacterial and Biological Properties of Poly(ɛ-caprolactone)/Biphasic Calcium Phosphate 3D-Scaffolds for Bone Tissue Engineering.
1/2023	Design, Characterization, and Biological Activities of Erythromycin-Loaded Nanodroplets to Counteract Infected Chronic Wounds Due to Streptococcus pyogenes.
1/2023	Immune Defences: A View from the Side of the Essential Oils.
1/2021	Antifungal Activity of Melaleuca alternifolia Essential Oil (TTO) and Its Synergy with Itraconazole or Ketoconazole against Trichophyton rubrum.
10/2017	The Microbiological@mind project: a public engagement initiative of Turin University bringing microbiology and health education into primary schools.
1/2016	Advances in Microbiology, Infectious Diseases and Public Health: Refractory Trichophyton rubrum Infections in Turin, Italy: A Problem Still Present.
10/2015	In vitro antifungal activity of fluconazole and voriconazole against non-Candida yeasts and yeast-like fungi clinical isolates.
1/2015	Antimicrobial chitosan nanodroplets: new insights for ultrasound-mediated adjuvant treatment of skin infection.
12/2011	Candida albicans infections in renal transplant recipients: effect of caspofungin on polymorphonuclear cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Narcisa Mandras Research Topics

Disease

10	Infections 02/2024 - 12/2011
4	Wounds and Injuries (Trauma) 01/2023 - 01/2015
2	Aspergillosis 10/2023 - 10/2021
2	Hypoxia (Hypoxemia) 01/2023 - 02/2021
2	Candidiasis (Moniliasis) 01/2023 - 08/2016
2	Mycoses (Diseases, Fungus) 08/2021 - 08/2019
1	Persistent Infection 01/2021
1	Drug-Related Side Effects and Adverse Reactions 08/2019
1	Tinea Capitis 01/2019
1	Invasive Candidiasis 12/2011
1	Invasive Fungal Infections 09/2010
1	Respiratory Tract Infections (Respiratory Tract Infection) 10/2004

Drug/Important Bio-Agent (IBA)

4	AzolesIBA 10/2023 - 09/2010
4	Volatile Oils (Essential Oils)IBA 01/2023 - 08/2016
3	Caspofungin (Cancidas)FDA Link 01/2023 - 09/2010
3	ChitosanIBA 01/2022 - 01/2015
2	SilverIBA 02/2024 - 08/2023
2	Itraconazole (Sporanox)FDA LinkGeneric 10/2023 - 01/2021
2	Biocompatible Materials (Biomaterials)IBA 08/2023 - 02/2021
2	Fluconazole (Zonal)FDA LinkGeneric 01/2023 - 10/2015
2	Oxygen (Dioxygen)IBA 01/2022 - 02/2021
2	TriazolesIBA 10/2021 - 01/2021
2	Antifungal AgentsIBA 08/2019 - 08/2016
1	Amphotericin B (Amphotericin)FDA LinkGeneric 10/2023
1	IonsIBA 08/2023
1	MetalsIBA 08/2023
1	Erythromycin (Erycette)FDA LinkGeneric 01/2023
1	diazonaphthalenedisulfonic acid (NDS)IBA 01/2023
1	Anidulafungin FDA Link 01/2023
1	Anti-Infective Agents (Microbicides)IBA 01/2023
1	2H,3H-decafluoropentaneIBA 02/2021
1	Biopolymers (Biopolymer)IBA 02/2021
1	Polysaccharides (Glycans)IBA 02/2021
1	Ketoconazole (Nizoral)FDA LinkGeneric 01/2021
1	ImidazolesIBA 01/2021
1	Anti-Bacterial Agents (Antibiotics)IBA 10/2017
1	Voriconazole (Vfend)FDA LinkGeneric 10/2015
1	ThiamphenicolIBA 10/2004

Therapy/Procedure

3	Therapeutics 01/2019 - 10/2015